ReproNovo
Lausanne, Switzerland · Founded 2021 · $62.0M raised
- Headquarters
- Lausanne
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- repronovo.com
- Total Funding
- $62.0M
- Last Round
- $62.0M Series AMay 2025
- Rounds
- 1
About
ReproNovo is a biopharmaceutical company developing innovative therapeutic solutions for reproductive medicine and women's health, including male and female infertility and uterine conditions like adenomyosis. Founded in 2021 and headquartered in Lausanne, Switzerland, the company has two Phase 2 clinical-stage assets: RPN-001 (leflutrozole) for male infertility and RPN-002 (nolasiban) for adenomyosis management and improved IVF outcomes.
Summary
ReproNovo is a Biotech company based in Lausanne, Switzerland, founded in 2021. It has raised $62.0M in total across 1 round, most recently a $62.0M Series A round in May 2025.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2025
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...